Harpoon Therapeutics Inc

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct? (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies.  Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it has closed a private placement of redeemable preferred stock and warrants to purchase common stock to certain institutional and other accredited investors for aggregate gross proceeds to the Company of $25 million, before deducting offering expenses, which does not include any proceeds that may be received upon exercise of the warrants.

Harpoon Therapeutics Announces Closing of $25 Million Private Placement

SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it will present data from five preclinical investigations in poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Fla., April 14-19, 2023.

Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will present at the virtual SVB Securities Global Biopharma Conference. The corporate presentation will take place on Tuesday, February 14, 2023 at 1:40 p.m. ET (10:40 a.m. PT).

Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Kinross Gold

Uranium Energy

If finding undervalued stocks is good, then finding undervalued penny stocks is even better. That's because, with penny stocks, investors' capital appreciation upside potential is amplified.

The 3 Most Undervalued Penny Stocks to Buy in February 2023

Everbridge

Global Water Resources

Richardson Electronics

Splunk

GWRS, EVBG, SPLK, RELL and HARP have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2023.

New Strong Buy Stocks for January 27th

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Harpoon Therapeutics, Inc. (HARP) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Why Fast-paced Mover Harpoon Therapeutics, Inc. (HARP) Is a Great Choice for Value Investors

CRISPR Therapeutics

Knightscope

Microvast Holdings

Rent the Runway

Soligenix

Solo Brands

There are few things that get growth investors excited like the opportunity to invest in 10x stocks. By definition, these 10x stocks (also referred to as 10 baggers) can add huge gains to your portfolio.

7 Stocks to Add to Your 10x Watchlist

Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.

Harpoon Therapeutics Remains Volatile After Promising News

Abeona Therapeutics

HTG Molecular Diagnostics

This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023

Three Small-Cap Biotech Stocks to Consider Now

Harpoon Therapeutics (NASDAQ: HARP ) stock is taking off on Monday following the release of updated results from its myeloma drug candidate. HPN217 is the company's drug candidate currently undergoing a Phase 1 clinical trial.

Why Is Harpoon Therapeutics (HARP) Stock Up 100%+ Today?

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented updated interim data from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma (RRMM) in a poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held in person and virtually in New Orleans. HPN217 targets B-cell maturation antigen (BCMA) and is based on Harpoon's proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient's own immune cells to kill tumor cells.

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review updated interim results of its Phase 1 HPN217 clinical program presented at the 64th American Society of Hematology (ASH) Annual Meeting and provide a corporate update.

Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. The discussion will take place on Wednesday, November 30, 2022 at 1:00 p.m. ET (10:00 a.m. PT).

Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 41.67% and 73.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Tops Revenue Estimates

HPN217 (BCMA) interim data update at ASH 2022; HPN328 (DLL3) exploring dosing regimens and HPN601 (EpCAM) expected to enter the clinic in 2023

Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results

Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma to be presented in a poster at ASH on Sunday, December 11, 2022, from 6:00 p.m. – 8:00 p.m. CT Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma to be presented in a poster at ASH on Sunday, December 11, 2022, from 6:00 p.m. – 8:00 p.m. CT

Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition

Harpoon adds experienced drug developer to leadership team Harpoon adds experienced drug developer to leadership team

Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer

Industry veteran Lauren Silvernail brings over 30 years of experience in financial leadership roles at life science and related companies Industry veteran Lauren Silvernail brings over 30 years of experience in financial leadership roles at life science and related companies

Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in three upcoming investor conferences:

Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences

Harpoon Therapeutics is an oncology platform play developing tri-specific drug candidates. The company's lead candidates HPN217 and HPN328 are in Phase 1/2 trials and have so far shown efficacy without compromising safety.

Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 3.64% and 9.95%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Harpoon Therapeutics, Inc. (HARP) Reports Q2 Loss, Misses Revenue Estimates

Presented encouraging interim data for anti-DLL3 T cell engager HPN328 from ongoing dose escalation clinical trial at the 2022 ASCO Annual Meeting

Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor conferences:

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

Harpoon Therapeutics has an intriguing platform that can generate stable bispecific immunotherapies using their TriTAC technology. Their “off-the-shelf” T-cell engagers help T-cells eliminate solid tumors and hematologic cancers. The company has several catalysts for its pipeline of four clinical assets this year that can validate the TriTAC platform.

News for Harpoon Therapeutics Inc Stock (HARP)